跳至主要内容
临床试验/NCT03588754
NCT03588754暂停2 期

Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking?

Yale University2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2018年9月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
暂停
入组人数
20
试验地点
2
主要终点
Alcohol consumption

研究概览

简要总结

For this protocol, the investigators plan to conduct a pilot study evaluating the effect of propranolol on alcohol consumption. Using a parallel design, the investigators plan to randomize 20 non-treatment seeking adults with alcohol use disorders (DSM-5) to propranolol extended release (160mg/day or placebo; n=10 per cell) to evaluate whether propranolol reduces alcohol self-administered in the laboratory. Importantly, the investigators will evaluate whether propranolol counteracts stress-induced effects on alcohol self-administration. Following titration to steady state medication levels over a 2-week period, each subject will complete two laboratory sessions consisting of a well validated method for inducing stress or neutral/relaxing state (order counterbalanced), followed by a 2-hour alcohol self-administration paradigm known to be sensitive to medication effects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
21 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Able to read and write English
  • Meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for current (past 6 months) alcohol use disorders
  • Able to take oral medications and willing to adhere to medication regimen

排除标准

  • Participants with any significant current medical conditions.
  • Women who are pregnant or nursing, or fail to use one of the following methods of birth control unless she or partner is surgically sterile or she is postmenopausal (hormone contraceptives [oral, implant, injection, patch, or ring], contraceptive sponge, double barrier [diaphragm or condom plus spermicide], or IUD)
  • Suicidal, homicidal or evidence of current (past 6-month) mental illness.
  • Specific exclusions for administration of propranolol not already specified.
  • Subjects likely to exhibit clinically significant alcohol withdrawal during the study.

研究组 & 干预措施

Placebo

Placebo Comparator

Administered orally once daily at 10:00PM

干预措施: Placebo (Drug)

Propranolol

Experimental

Propranolol extended release (160mg/day). Administered orally once daily at 10:00PM. Titration schedule Days 1-3 60mg, Days 4-7 80mg, Days 8-11 120mg, and Days 12-14 160mg until steady state.

干预措施: Propranolol (Drug)

结局指标

主要结局

Alcohol consumption

时间窗: 120 minutes

Mean mls of alcohol consumed (maximum of 120 mg/dL) for propranolol and placebo groups during 120 minute alcohol self administration sessions taking place as close to Day 15 and Day 19 as possible of medication dosing.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

已完成
2 期
Propranolol for the Treatment of Acute Stress DisorderStress Disorders, Traumatic, Acute
NCT00069355National Institute of Mental Health (NIMH)50
已完成
早期 1 期
Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Undifferentiated CarcinomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous AdenocarcinomaOvarian Undifferentiated CarcinomaPrimary Peritoneal Serous AdenocarcinomaStage II Fallopian Tube Cancer AJCC v6 and v7Stage II Ovarian Cancer AJCC v6 and v7Stage IIA Fallopian Tube Cancer AJCC v6 and v7Stage IIA Ovarian Cancer AJCC V6 and v7Stage IIB Fallopian Tube Cancer AJCC v6 and v7Stage IIB Ovarian Cancer AJCC v6 and v7Stage IIC Fallopian Tube Cancer AJCC v6 and v7Stage IIC Ovarian Cancer AJCC v6 and v7Stage III Fallopian Tube Cancer AJCC v7Stage III Ovarian Cancer AJCC v6 and v7Stage III Primary Peritoneal Cancer AJCC v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIA Ovarian Cancer AJCC v6 and v7Stage IIIA Primary Peritoneal Cancer AJCC v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IIIB Ovarian Cancer AJCC v6 and v7Stage IIIB Primary Peritoneal Cancer AJCC v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IIIC Ovarian Cancer AJCC v6 and v7Stage IIIC Primary Peritoneal Cancer AJCC v7Stage IV Fallopian Tube Cancer AJCC v6 and v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IV Primary Peritoneal Cancer AJCC v7
NCT01504126M.D. Anderson Cancer Center32
已完成
2 期
Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT RecipientsMultiple Myeloma
NCT02420223Medical College of Wisconsin25
Unknown
不适用
Effect of Propranolol on the Autonomic Nervous System and Muscle PainTemporomandibular Joint DisordersMyofascial Temporomandibular Disorders
NCT01333150University of Aarhus16
已完成
3 期
Beta-Blocker Heart Attack Trial (BHAT)Cardiovascular DiseasesCoronary DiseaseDeath, Sudden, CardiacHeart DiseasesVentricular FibrillationMyocardial InfarctionMyocardial IschemiaArrhythmia
NCT00000492National Heart, Lung, and Blood Institute (NHLBI)